Ricardo Bhatt

Ricardo Bhatt investigates the clinical translation of neutrophil-targeted cancer immunotherapy, studying how the neutrophil-to-lymphocyte ratio (NLR) predicts immunotherapy outcomes and developing strategies to deplete or reprogram immunosuppressive neutrophils in combination with checkpoint blockade. His clinical research has validated NLR as a prognostic biomarker across multiple cancer types treated with immunotherapy. He has contributed to clinical trials of CXCR2 inhibitors in combination with anti-PD-1 therapy. His translational work bridges neutrophil biology and clinical oncology practice.